Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, April 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 164 articles:
HTML format


 

Single Articles

  1. TURATI F, Bosetti C, Polesel J, Serraino D, et al
    Family history of cancer and the risk of bladder cancer: A case-control study from Italy.
    Cancer Epidemiol. 2017;48:29-35.
    Abstract    

    Abstract available

  2. WOLDU SL, Sanli O, Lotan Y
    Tackling Non-Muscle Invasive Bladder Cancer in the Clinic.
    Expert Rev Anticancer Ther. 2017 Mar 31. doi: 10.1080/14737140.2017.1313119.
    Abstract    

    Abstract available

  3. KASMANN L, Manig L, Janssen S, Rades D, et al
    Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients.
    In Vivo. 2017;31:239-241.
    Abstract    

    Abstract available

  4. AOUN F, Rassy EE, Assi T, Albisinni S, et al
    Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
    Immunotherapy. 2017;9:451-460.
    Abstract    

    Abstract available

  5. CHENG N, Xu Y, Luo Y, Zhu L, et al
    Specific and relative detection of urinary microRNA signatures in bladder cancer for point-of-care diagnostics.
    Chem Commun (Camb). 2017 Mar 30. doi: 10.1039/c7cc01007.
    Abstract    

    Abstract available

  6. WANG H, Zuo Y, Ding M, Ke C, et al
    LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity.
    Oncol Lett. 2017;13:661-668.
    Abstract    

    Abstract available

  7. TSAI JL, Tsai SF
    Calcium oxalate crystal related kidney injury in a patient receiving Roux-en Y hepaticojejunostomy due to gall bladder cancer.
    BMC Nephrol. 2017;18:106.
    Abstract    

    Abstract available

  8. SUNDAR RAJAN V, Laurent VM, Verdier C, Duperray A, et al
    Unraveling the Receptor-Ligand Interactions between Bladder Cancer Cells and the Endothelium Using AFM.
    Biophys J. 2017;112:1246-1257.
    Abstract    

    Abstract available

  9. SIDAWAY P
    Bladder cancer: TCGA cohort is representative of invasive disease.
    Nat Rev Urol. 2017 Mar 29. doi: 10.1038/nrurol.2017.
    Abstract    



  10. SON SK, Lee NR, Kang SH, Lee SH, et al
    Safety and Effectiveness of Robot-Assisted Versus Open Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    J Laparoendosc Adv Surg Tech A. 2017 Mar 28. doi: 10.1089/lap.2016.0437.
    Abstract    

    Abstract available

  11. CHIU M, McBeth L, Sindhwani P, Hinds TD, et al
    Deciphering the Roles of Thiazolidinediones and PPARgamma in Bladder Cancer.
    PPAR Res. 2017;2017:4810672.
    Abstract    

    Abstract available

  12. OLIVEIRA MB, Villa Nova M, Bruschi ML
    A review of recent developments on micro/nanostructured pharmaceutical systems for intravesical therapy of the bladder cancer.
    Pharm Dev Technol. 2017 Mar 27:1-43. doi: 10.1080/10837450.2017.1312441.
    Abstract    

    Abstract available

  13. MOUW KW
    DNA Repair Pathway Alterations in Bladder Cancer.
    Cancers (Basel). 2017;9.
    Abstract    

    Abstract available

  14. VALE N, Gouveia MJ, Rinaldi G, Santos J, et al
    The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer.
    Tumour Biol. 2017;39:1010428317692247.
    Abstract    

    Abstract available

  15. ZHANG H, Fan Y, Xia L, Gao C, et al
    The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.
    Tumour Biol. 2017;39:1010428317691183.
    Abstract    

    Abstract available

  16. QU K, Gu J, Ye Y, Williams SB, et al
    High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.
    Oncoimmunology. 2017;6:e1265719.
    Abstract    

    Abstract available

  17. SORIA F, Lucca I, Moschini M, Mathieu R, et al
    Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.
    Urol Oncol. 2017 Mar 22. pii: S1078-1439(17)30093.
    Abstract    

    Abstract available

  18. SIKIC D, Breyer J, Hartmann A, Burger M, et al
    High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.
    Transl Oncol. 2017;10:340-345.
    Abstract    

    Abstract available

  19. SATO A, Asano T, Okubo K, Isono M, et al
    Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
    Cancer Sci. 2017 Mar 25. doi: 10.1111/cas.13242.
    Abstract    

    Abstract available

  20. SEITZ AK, Christensen LL, Christensen E, Faarkrog K, et al
    Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer.
    Sci Rep. 2017;7:395.
    Abstract    

    Abstract available

  21. DONIN NM, Chamie K, Lenis AT, Pantuck AJ, et al
    A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
    Urol Oncol. 2017;35:39.
    Abstract    

    Abstract available

  22. MENG FM, Meng FM, Song XL
    MiR-576-3p is a novel marker correlated with poor clinical outcome in bladder cancer.
    Eur Rev Med Pharmacol Sci. 2017;21:973-977.
    Abstract    

    Abstract available

  23. WANG R, Wu Y, Huang W, Chen W, et al
    MicroRNA-940 Targets INPP4A or GSK3beta and Activates the Wnt/beta-Catenin Pathway to Regulate the Malignant Behavior of Bladder Cancer Cells.
    Oncol Res. 2017 Mar 23. doi: 10.3727/096504017X14902261600566.
    Abstract    

    Abstract available

  24. FINA E, Necchi A, Bottelli S, Reduzzi C, et al
    Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods.
    Dis Markers. 2017;2017:3414910.
    Abstract    

    Abstract available

  25. MD NOH MS, Abdul Aziz AF, Mohd Ghani KA, Lee Kheng Siang C, et al
    Giant Intradiverticular Bladder Tumor.
    Am J Case Rep. 2017;18:212-216.
    Abstract    

    Abstract available

  26. CHO A, Lee SM, Noh JW, Choi DK, et al
    Acid-base disorders after orthotopic bladder replacement: comparison of an ileal neobladder and an ileal conduit.
    Ren Fail. 2017;39:379-384.
    Abstract    

    Abstract available

  27. LOBO J, Henrique R, Monteiro P, Lobo C, et al
    ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review.
    Diagn Cytopathol. 2017;45:354-358.
    Abstract    

    Abstract available

  28. ISHIBASHI N, Maebayashi T, Aizawa T, Sakaguchi M, et al
    Refractory Haematuria Resulting From Peritoneal Dissemination of Metastatic Gastric Cancer: Radiation Therapy For A Nodule Infiltrating The Urinary Bladder.
    Urol J. 2017;14:2982-2984.
    Abstract    

    Abstract available

  29. LEE J, Park S, Cho MS, Sung SH, et al
    Urine cytology findings of primary paraganglioma of the urinary bladder: Case report.
    Diagn Cytopathol. 2017;45:350-353.
    Abstract    

    Abstract available

  30. LIU X, Wei M, Xu E, Yang H, et al
    A sensitive, label-free electrochemical detection of telomerase activity without modification or immobilization.
    Biosens Bioelectron. 2017;91:347-353.
    Abstract    

    Abstract available

  31. LV M, Zhong Z, Chi H, Huang M, et al
    Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin beta1 Signaling Pathways in Bladder Carcinoma.
    Int J Mol Sci. 2016;18.
    Abstract    

    Abstract available

  32. POLLARD RE, Watson KD, Hu X, Ingham E, et al
    Feasibility of quantitative contrast ultrasound imaging of bladder tumors in dogs.
    Can Vet J. 2017;58:70-72.
    Abstract    

    Abstract available

  33. BROWN KG, Solomon MJ, Latif ER, Koh CE, et al
    Urological complications after cystectomy as part of pelvic exenteration are higher than that after cystectomy for primary bladder malignancy.
    J Surg Oncol. 2017;115:307-311.
    Abstract    

    Abstract available

  34. WANG ZY, Zhang W, Yang JJ, Song DK, et al
    Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.
    J Huazhong Univ Sci Technolog Med Sci. 2016;36:705-709.
    Abstract    

    Abstract available

  35. ARAKAWA K, Ishihara S, Kawai K, Shibata J, et al
    Asynchronous bilateral anastomosis site sigmoid colon cancer after ureterosigmoidostomy: a case report.
    World J Surg Oncol. 2016;14:180.
    Abstract    

    Abstract available

  36. HEDEGAARD J, Lamy P, Nordentoft I, Algaba F, et al
    Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
    Cancer Cell. 2016;30:27-42.
    Abstract    

    Abstract available

  37. SAUER M, Degen O, Beyersdorff D
    [Not Available].
    Rofo. 2016;188:782-3.
    Abstract    



  38. PANG C, Guan Y, Li H, Chen W, et al
    Urologic cancer in China.
    Jpn J Clin Oncol. 2016;46:497-501.
    Abstract    

    Abstract available

  39. ISMAILI N
    External beam radiation therapy for small cell carcinoma of the bladder.
    Pract Radiat Oncol. 2016;6:e215-6.
    Abstract    



  40. KONG V, Kwan M, Chen S, Moseley J, et al
    Impact of image registration surrogates on the planning target volume geometry for bladder radiation therapy.
    Pract Radiat Oncol. 2016;6:e187-94.
    Abstract    

    Abstract available

  41. SALAH S, Lee JL, Rozzi A, Kitamura H, et al
    Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Clin Genitourin Cancer. 2016;14:255-60.
    Abstract    

    Abstract available

  42. JAN AS, Dolan DE, Lombardi K, Gupta S, et al
    Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
    Clin Genitourin Cancer. 2016;14:e257-63.
    Abstract    

    Abstract available

  43. ANTONELLI A, Belotti S, Cristinelli L, De Luca V, et al
    Comparison of Perioperative Morbidity of Radical Cystectomy With Neobladder Versus Ileal Conduit: A Matched Pair Analysis of 170 Patients.
    Clin Genitourin Cancer. 2016;14:244-8.
    Abstract    

    Abstract available

  44. TAGUCHI S, Akamatsu N, Nakagawa T, Gonoi W, et al
    Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2016;14:237-43.
    Abstract    

    Abstract available

  45. TAJIMA S, Suzuki T, Yamada Y, Morikawa T, et al
    Invasive urothelial carcinoma with chordoid features may be an ominous sign predicting sarcomatoid change: a case report of a bladder carcinoma.
    Med Mol Morphol. 2016;49:182-7.
    Abstract    

    Abstract available

  46. DU L, Jiang X, Duan W, Wang R, et al
    Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
    Oncotarget. 2017 Mar 28. doi: 10.18632/oncotarget.16586.
    Abstract    

    Abstract available

  47. KIM YJ, Byun SJ, Ahn H, Kim CS, et al
    Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Oncotarget. 2017 Mar 25. doi: 10.18632/oncotarget.16576.
    Abstract    

    Abstract available

  48. CHLOSTA PL, Golabek T, Nyirady P
    New Insights into Diagnosis and Treatment of Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer.
    Biomed Res Int. 2017;2017:6467072.
    Abstract    



  49. YU H, Duan P, Zhu H, Rao D, et al
    miR-613 inhibits bladder cancer proliferation and migration through targeting SphK1.
    Am J Transl Res. 2017;9:1213-1221.
    Abstract    

    Abstract available

  50. TAN G, Wang H, Yuan J, Qin W, et al
    Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
    Sci Rep. 2017;7:46176.
    Abstract    

    Abstract available

  51. WU J, Wan F, Sheng H, Shi G, et al
    NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer.
    J Cancer. 2017;8:852-860.
    Abstract    

    Abstract available

  52. LI Y, Guo G, Song J, Cai Z, et al
    B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway.
    J Cancer. 2017;8:816-824.
    Abstract    

    Abstract available

  53. EISSA S, Matboli M, Awad N, Kotb Y, et al
    Identification and validation of a novel autophagy gene expression signature for human bladder cancer patients.
    Tumour Biol. 2017;39:1010428317698360.
    Abstract    

    Abstract available

  54. MINAMI K, Taniguchi K, Sugito N, Kuranaga Y, et al
    MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cells.
    Oncotarget. 2017 Mar 23. doi: 10.18632/oncotarget.16524.
    Abstract    

    Abstract available

  55. WANG X, Zhang F, Wu XR
    Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
    Sci Rep. 2017;7:45983.
    Abstract    

    Abstract available

  56. KUMARI N, Agrawal U, Mishra AK, Kumar A, et al
    Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer.
    Tumour Biol. 2017;39:1010428317697552.
    Abstract    

    Abstract available

  57. JIANG H, Hu X, Zhang H, Li W, et al
    Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression.
    Radiat Oncol. 2017;12:65.
    Abstract    

    Abstract available

  58. EL-ARABEY AA
    New insight for metformin against bladder cancer.
    Genes Environ. 2017;39:13.
    Abstract    

    Abstract available

  59. LEVINE JJ, Somer RA, Hosoya H, Squillante C, et al
    Atezolizumab-induced Encephalitis in Metastatic Bladder Cancer: A Case Report and Review of the Literature.
    Clin Genitourin Cancer. 2017 Mar 16. pii: S1558-7673(17)30063.
    Abstract    



  60. LI Y, Shan Z, Liu C, Yang D, et al
    MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer.
    Biochemistry (Mosc). 2017;82:474-482.
    Abstract    

    Abstract available

  61. KLUMPER N, Syring I, Vogel W, Schmidt D, et al
    Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.
    Front Med (Lausanne). 2017;4:30.
    Abstract    

    Abstract available

  62. KONG DB, Chen F, Sima N
    Focal adhesion kinases crucially regulate TGFbeta-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin.
    Onco Targets Ther. 2017;10:1783-1792.
    Abstract    

    Abstract available

  63. LUO F, Wang YS, Su YH, Zhang ZH, et al
    Prognostic impact of preoperative anemia on non-muscle-invasive bladder carcinoma treated with GreenLight laser vaporization.
    Lasers Med Sci. 2017;32:397-403.
    Abstract    

    Abstract available

  64. KHACHATRYAN A
    [THE EARLY DIAGNOSTICS OF MULTIPLE PRIMARY TUMORS OF MALE UROGENITAL TRACT (REVIEW OF CLINICAL CASES)].
    Georgian Med News. 2016;.
    Abstract    

    Abstract available

  65. FAGHIH Z, Shobeiri SS, Ariafar A, Sarkarian M, et al
    CD8+ T Lymphocyte Subsets in Bladder Tumor Draining Lymph Nodes.
    Iran J Immunol. 2016;13:237-248.
    Abstract    

    Abstract available

  66. LENOS M, Katafigiotis I, Vrettou K, Papaioannou D, et al
    Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis.
    Cytopathology. 2017;28:96-102.
    Abstract    

    Abstract available

  67. NAKAMURA T
    Development of a Drug Delivery System for Cancer Immunotherapy.
    Yakugaku Zasshi. 2016;136:1477-1484.
    Abstract    

    Abstract available

  68. MIKI Y, Neat M, Chandra A
    Application of The Paris System to atypical urine cytology samples: correlation with histology and UroVysion(R) FISH.
    Cytopathology. 2017;28:88-95.
    Abstract    

    Abstract available

  69. LEIVO MZ, Elson PJ, Tacha DE, Delahunt B, et al
    A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
    Pathology. 2016;48:543-9.
    Abstract    

    Abstract available

  70. TIAN DW, Hu HL, Sun Y, Tang Y, et al
    Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs.
    Mol Med Rep. 2016;14:1553-9.
    Abstract    

    Abstract available

  71. HINRICHSEN S, Planer-Friedrich B
    Cytotoxic activity of selenosulfate versus selenite in tumor cells depends on cell line and presence of amino acids.
    Environ Sci Pollut Res Int. 2016;23:8349-57.
    Abstract    

    Abstract available

  72. SANLI O, Dobruch J, Knowles MA, Burger M, et al
    Bladder cancer.
    Nat Rev Dis Primers. 2017;3:17022.
    Abstract    

    Abstract available


  73. Bladder cancer.
    Nat Rev Dis Primers. 2017;3:17023.
    Abstract    



  74. DAVIES BJ, Hwang TJ, Kesselheim AS
    Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
    N Engl J Med. 2017;376:1401-1403.
    Abstract    



  75. WANG LH, Lei S, Dong Yuan S, Che X, et al
    Long-term floating control-released intravesical preparation of 5-fluorouracil for the local treatment of bladder cancer.
    Drug Dev Ind Pharm. 2017 Apr 12:1-21. doi: 10.1080/03639045.2017.1318898.
    Abstract    

    Abstract available

  76. NIEDERSUSS-BEKE D, Puntus T, Kunit T, Grunberger B, et al
    Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
    Oncology. 2017 Apr 12. doi: 10.1159/000463389.
    Abstract    

    Abstract available

  77. PANER GP, Montironi R, Amin MB
    Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    Adv Anat Pathol. 2017;24:113-127.
    Abstract    

    Abstract available

  78. PATSCHAN O, Holmang S, Hosseini A, Jancke G, et al
    Second-look resection for primary stage T1 bladder cancer: a population-based study.
    Scand J Urol. 2017 Apr 11:1-7. doi: 10.1080/21681805.2017.1303846.
    Abstract    

    Abstract available

  79. KUSAKA A, Hatakeyama S, Hosogoe S, Hamano I, et al
    Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer.
    Med Oncol. 2017;34:90.
    Abstract    

    Abstract available

  80. ZHAO L, Tian X, Duan X, Ye Y, et al
    Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies.
    Oncotarget. 2017 Mar 30. doi: 10.18632/oncotarget.16722.
    Abstract    

    Abstract available

  81. LI Y, Wen JM, Du CJ, Hu SM, et al
    Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis.
    Biochem Biophys Res Commun. 2017 Apr 4. pii: S0006-291X(17)30666.
    Abstract    

    Abstract available

  82. MALMSTROM PU, Hemdan T, Segersten U
    Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer.
    Urol Oncol. 2017 Apr 4. pii: S1078-1439(17)30110.
    Abstract    

    Abstract available

  83. CHALA B, Choi MH, Moon KC, Kim HS, et al
    Development of Urinary Bladder Pre-Neoplasia by Schistosoma haematobium Eggs and Chemical Carcinogen in Mice.
    Korean J Parasitol. 2017;55:21-29.
    Abstract    

    Abstract available

  84. SHARMA A, Mete UK, Sood A, Kakkar N, et al
    Utility of early dynamic and delayed post-diuretic 18F-FDG PET/CT SUVmax in predicting tumor grade and T-stage of urinary bladder carcinoma: Results from a prospective single center study.
    Br J Radiol. 2017 Mar 3:20160787. doi: 10.1259/bjr.20160787.
    Abstract    

    Abstract available

  85. AI XL, Chi Q, Qiu Y, Li HY, et al
    Gap junction protein connexin43 deregulation contributes to bladder carcinogenesis via targeting MAPK pathway.
    Mol Cell Biochem. 2017;428.
    Abstract    

    Abstract available

  86. LEMBO F, Subba E, Lagana AS, Vitale SG, et al
    Intradiverticular Sarcomatoid Carcinoma of The Bladder: An Overview Starting From A Peculiar Case.
    Urol J. 2016;13:2800-2.
    Abstract    



  87. WU SW, Liou JH, Yeh KT, Hung TW, et al
    The Prevalence and Prognostic Significance of Polyomavirus Infection in Patients with Urothelial Carcinoma of the Bladder.
    Urol J. 2016;13:2773-8.
    Abstract    

    Abstract available

  88. BARNES SC, Shepherd DE, Espino DM, Bryan RT, et al
    Design of an improved surgical instrument for the removal of bladder tumours.
    Proc Inst Mech Eng H. 2016;230:579-87.
    Abstract    

    Abstract available

  89. SHRADER S, Lauridson J, King Z, Loch J, et al
    Urachal Adenocarcinoma in a Dog.
    J Comp Pathol. 2016;154:304-8.
    Abstract    

    Abstract available

  90. GUO S, Fan C, Rohr J, Fan L, et al
    A clinicopathologic study of paragangliomas of the urinary bladder: can the clinical behavior of the tumor be predicted?
    Histol Histopathol. 2016;31:785-91.
    Abstract    

    Abstract available

  91. NOVOTNY V, Froehner M, Koch R, Zastrow S, et al
    Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy.
    World J Urol. 2016;34:1123-9.
    Abstract    

    Abstract available

  92. COMBERG D, Gauer A, Tschernig T
    First findings of gap junction proteins in human urothelial carcinoma.
    World J Urol. 2016;34:145-7.
    Abstract    



  93. HUANG XL, Zhang H, Yang XY, Dong XY, et al
    Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
    Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000499.
    Abstract    

    Abstract available

  94. BACCHETTI T, Sartini D, Pozzi V, Cacciamani T, et al
    Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell cultures.
    Oncotarget. 2017 Feb 24. doi: 10.18632/oncotarget.15674.
    Abstract    

    Abstract available

  95. EICH ML, Dyrskjot L, Netto GJ
    Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
    Virchows Arch. 2017 Apr 21. doi: 10.1007/s00428-017-2119.
    Abstract    

    Abstract available

  96. HAU AM, Nakasaki M, Nakashima K, Krish G, et al
    Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition.
    Urol Oncol. 2017 Apr 18. pii: S1078-1439(17)30134.
    Abstract    

    Abstract available

  97. YANG LL, Wang XY, Zheng LY, Fang SJ, et al
    [The role of FOXO3a-Bim signaling in triptolide induced bladder cancer T24 cells apoptosis].
    Zhonghua Yi Xue Za Zhi. 2017;97:1187-1190.
    Abstract    

    Abstract available

  98. OZGOZ A, Samli M, Dincel D, Sahin A, et al
    Association of B7-H4 gene polymorphisms in urothelial bladder cancer.
    Turk J Med Sci. 2017;47:443-446.
    Abstract    

    Abstract available

  99. LIU X, Liu X, Wu Y, Wu Q, et al
    MicroRNAs in biofluids are novel tools for bladder cancer screening.
    Oncotarget. 2017 Mar 8. doi: 10.18632/oncotarget.16026.
    Abstract    

    Abstract available

  100. LEONE A, Diorio G, Sexton W, Schell M, et al
    Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.
    Oncotarget. 2017 Mar 8. doi: 10.18632/oncotarget.16015.
    Abstract    

    Abstract available

  101. POYET C, Thomas L, Benoit TM, Delmo DA, et al
    Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.
    Oncotarget. 2017;8:21871-21883.
    Abstract    

    Abstract available

  102. CHEN L, Pan XW, Huang H, Gao Y, et al
    Epithelial-mesenchymal transition induced by GRO-alpha-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy.
    Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16786.
    Abstract    

    Abstract available

  103. STYRKE J, Henriksson H, Ljungberg B, Hasan M, et al
    Evaluation of the diagnostic accuracy of UBC(R) Rapid in bladder cancer: a Swedish multicentre study.
    Scand J Urol. 2017 Apr 19:1-8. doi: 10.1080/21681805.2017.1313309.
    Abstract    

    Abstract available

  104. SUN F, Zhao R, Zhu Y, Cui D, et al
    A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
    Cancer Chemother Pharmacol. 2017 Apr 18. doi: 10.1007/s00280-017-3305.
    Abstract    

    Abstract available

  105. D'ANDREA D, Moschini M, Gust K, Abufaraj M, et al
    Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Mar 27. pii: S1558-7673(17)30069.
    Abstract    

    Abstract available

  106. YANG G, Shen W, Zhang Y, Liu M, et al
    Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer.
    Oncotarget. 2017 Mar 20. doi: 10.18632/oncotarget.16386.
    Abstract    

    Abstract available

  107. DUDEK AM, Boer SJ, Boon N, Witjes JA, et al
    Identification of long non-coding RNAs that stimulate cell survival in bladder cancer.
    Oncotarget. 2017 Mar 16. doi: 10.18632/oncotarget.16284.
    Abstract    

    Abstract available

  108. CHEN C, Hu L, Chen Y, Hou J, et al
    The prognostic value of histological subtype in patients with metastatic bladder cancer.
    Oncotarget. 2017 Mar 10. doi: 10.18632/oncotarget.16083.
    Abstract    

    Abstract available

  109. CUI X, Jing X, Long C, Yi Q, et al
    Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis.
    Oncotarget. 2017 Mar 22. doi: 10.18632/oncotarget.16473.
    Abstract    

    Abstract available

  110. SHAO CH, Chen CL, Lin JY, Chen CJ, et al
    Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
    Oncotarget. 2017 Mar 21. doi: 10.18632/oncotarget.16393.
    Abstract    

    Abstract available

  111. WEI Y, Gao L, Wang L, Shi L, et al
    Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
    Drug Deliv. 2017;24:681-691.
    Abstract    

    Abstract available

  112. LEONE AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, et al
    Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience.
    Clin Genitourin Cancer. 2017 Feb 1. pii: S1558-7673(17)30030.
    Abstract    

    Abstract available

  113. SURYAVANSHI M, Sanz-Ortega J, Sirohi D, Divatia MK, et al
    S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers.
    Adv Anat Pathol. 2017;24:151-160.
    Abstract    

    Abstract available

  114. ELHAWARY NA, Nassir A, Saada H, Dannoun A, et al
    Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.
    Dis Markers. 2017;2017:1474560.
    Abstract    

    Abstract available

  115. AMAYA CN, Wians FH Jr, Bryan BA, Torabi A, et al
    Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.
    Pathology. 2017;49:292-296.
    Abstract    

    Abstract available

  116. BIGOT F, Bonnet C, Massard C
    [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bull Cancer. 2017;104:370-379.
    Abstract    

    Abstract available

  117. FUKUSHIMA K, Hirosako S, Tenjin Y, Mukasa Y, et al
    Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with Spontaneous Regression after Computed Tomography-guided Needle Biopsy: A Case Report and Summary of 8 Reported Cases.
    Intern Med. 2016;55:3655-3660.
    Abstract    

    Abstract available

  118. WANG H, Yuan G, Zhao B, Zhao Y, et al
    High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma.
    Mol Med Rep. 2017;15:743-749.
    Abstract    

    Abstract available

  119. PASCHKE L, Juszczak M, Slupski M
    Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
    World J Surg Oncol. 2016;14:296.
    Abstract    

    Abstract available

  120. CHO MH, Kim SH, Park WS, Joung JY, et al
    Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
    World J Surg Oncol. 2016;14:270.
    Abstract    

    Abstract available

  121. SEVINC C, Ozkaptan O, Balaban M, Yucetas U, et al
    Radical Cystoprostatectomy in Patients with Behcet's Disease: The Report of Four Cases and Review of The Literature.
    Urol J. 2016;13:2871-2875.
    Abstract    



  122. MAI KT, Bateman J, Djordjevic B, Flood TA, et al
    Clear Cell Urothelial Carcinoma.
    Int J Surg Pathol. 2017;25:18-25.
    Abstract    

    Abstract available

  123. RAIS-BAHRAMI S, Tracht JP, McIntosh ER, Lai WS, et al
    Complete Tissue Submission to Increase Lymph Node Detection in Pelvic Lymph Node Packets Submitted for Patients Undergoing Radical Prostatectomy and Radical Cystectomy.
    Int J Surg Pathol. 2017;25:12-17.
    Abstract    

    Abstract available

  124. YIKILMAZ TN, Dirim A, Ayva ES, Ozdemir H, et al
    Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin.
    Urol J. 2016;13:2677-83.
    Abstract    

    Abstract available

  125. GOTO K
    CD138 Expression Is Observed in the Urothelial Epithelium and in Various Urothelial Carcinomas, and Cannot Be Evidence for Plasmacytoid Urothelial Carcinoma.
    Int J Surg Pathol. 2016;24:614-9.
    Abstract    

    Abstract available

  126. MAY M, Fritsche HM, Vetterlein MW, Bastian PJ, et al
    Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011.
    World J Urol. 2017;35:245-250.
    Abstract    

    Abstract available

  127. GOLABEK T, Palou J, Rodriguez O, Gaya JM, et al
    Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy?
    World J Urol. 2017;35:237-243.
    Abstract    

    Abstract available

  128. LIU CW, Wu YT, Lin KJ, Yu TJ, et al
    A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
    Molecules. 2016;21.
    Abstract    

    Abstract available

  129. ANGELINI L, Bisogno G, Alaggio R, Scarzello G, et al
    Prognostic factors in children undergoing salvage surgery for bladder/prostate rhabdomyosarcoma.
    J Pediatr Urol. 2016;12:265.
    Abstract    

    Abstract available

  130. SHAO IH, Chang YH, Yu KJ, Lin PH, et al
    Outcomes and prognostic factors of simple partial cystectomy for localized bladder urothelial cell carcinoma.
    Kaohsiung J Med Sci. 2016;32:191-5.
    Abstract    

    Abstract available

  131. LODH B, Sinam RS, Singh KA
    Adenocarcinoma of urinary bladder in patient with primary gastric cancer: An unusual synchronous distant metastasis.
    Indian J Cancer. 2016;53:53-5.
    Abstract    



  132. DOGANTEKIN E, Girgin C, Gorgel SN, Soylemez H, et al
    Can immediate second resection be an alternative to standardized second transurethral resection of bladder tumors?
    Kaohsiung J Med Sci. 2016;32:147-51.
    Abstract    

    Abstract available

  133. KURTIS B, Zhuge J, Ojaimi C, Ye F, et al
    Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Ann Diagn Pathol. 2016;21:7-11.
    Abstract    

    Abstract available

  134. MITRA S, Sundaram AK, Gupta K, Devana SK, et al
    Urothelial Carcinoma With Villoglandular Differentiation: A Rare Entity.
    Int J Surg Pathol. 2016;24:356-9.
    Abstract    

    Abstract available

  135. VILLA L, Cloutier J, Letendre J, Ploumidis A, et al
    Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.
    World J Urol. 2016;34:1201-6.
    Abstract    

    Abstract available

  136. BREYER J, Gierth M, Shalekenov S, Aziz A, et al
    Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    World J Urol. 2016;34:709-16.
    Abstract    

    Abstract available

  137. GRIMM T, Buchner A, Schneevoigt B, Kretschmer A, et al
    Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.
    World J Urol. 2016;34:703-8.
    Abstract    

    Abstract available

  138. ZARGAR-SHOSHTARI K, Zargar H, Dinney CP, Ercole CE, et al
    Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
    World J Urol. 2016;34:695-701.
    Abstract    

    Abstract available

  139. MATEU L, Garcia-Cruz E, Asiain I, Castaneda R, et al
    A higher Charlson comorbidity index is related to more aggressive characteristics in de novo vesical tumours.
    Actas Urol Esp. 2016;40:23-8.
    Abstract    

    Abstract available

  140. HANAZONO K, Nishimori T, Fukumoto S, Kawamura Y, et al
    Immunohistochemical expression of p63, Ki67 and beta-catenin in canine transitional cell carcinoma and polypoid cystitis of the urinary bladder.
    Vet Comp Oncol. 2016;14:263-9.
    Abstract    

    Abstract available

  141. SILVA J, Arantes-Rodrigues R, Pinto-Leite R, Faustino-Rocha AI, et al
    Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.
    Anticancer Res. 2017;37:1737-1745.
    Abstract    

    Abstract available

  142. HUDOLIN T, Mengus C, Coulot J, Kastelan Z, et al
    Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
    Anticancer Res. 2017;37:1375-1380.
    Abstract    

    Abstract available

  143. SHI CS, Li JM, Chin CC, Kuo YH, et al
    Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2017;37:1149-1159.
    Abstract    

    Abstract available

  144. HAYNE D, Stockler M, McCombie SP, Lawrence N, et al
    The BCG + Mitomycin trial for high risk non-muscle-invasive bladder cancer: Progress report and lessons learned.
    BJU Int. 2017 Apr 9. doi: 10.1111/bju.13873.
    Abstract    

    Abstract available

  145. NICHOLSON J, Jevons S, Groselj B, Ellermann S, et al
    E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
    Cancer Res. 2017 Mar 31. pii: canres.3232.2016.
    Abstract    

    Abstract available

  146. YANG L, Taylor J, Eustace A, Irlam J, et al
    A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High Risk Bladder Cancer Patients.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0038.2017.
    Abstract    

    Abstract available

  147. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    Abstract    

    Abstract available

  148. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    Abstract    

    Abstract available

  149. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    Abstract    

    Abstract available

  150. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    Abstract    



  151. KULKARNI GS, Hermanns T, Wei Y, Bhindi B, et al
    Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Clin Oncol. 2017 Apr 14:JCO2016692327. doi: 10.1200/JCO.2016.69.2327.
    Abstract    

    Abstract available

  152. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.
    Abstract    



  153. BA M, Cui S, Wang B, Long H, et al
    Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection.
    Oncol Rep. 2017;37:2761-2770.
    Abstract    

    Abstract available

  154. ALIMI Q, Peyronnet B, Kammerer-Jacquet SF, Lefevre M, et al
    [Oncologic and perioperative outcomes of robot-assisted radical cystectomy: A single-center prospective series].
    Prog Urol. 2016;26:538-46.
    Abstract    

    Abstract available

  155. BALCI M, Tuncel A, Keten T, Guzel O, et al
    Comparison of Monopolar and Bipolar Transurethral Resection of Non-Muscle Invasive Bladder Cancer.
    Urol Int. 2017 Apr 6. doi: 10.1159/000467397.
    Abstract    

    Abstract available

  156. GAKIS G, Efstathiou JA, Daneshmand S, Keegan KA, et al
    Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.
    Urol Int. 2016;97:134-41.
    Abstract    

    Abstract available

  157. D''AGOSTINO D, Racioppi M, Pugliese D, Ragonese M, et al
    Postoperative Quality of Life in Patients with Ileal Neobladder at Short-, Intermediate- and Long-Term Follow-Up.
    Urol Int. 2016;97:54-60.
    Abstract    

    Abstract available

  158. KLAASSEN Z, Soloway MS
    EAU and AUA/SUO Guidelines on Risk Categories for Non-Muscle Invasive Bladder Cancer May Lead to Overtreatment for Low Grade Ta Bladder Tumors.
    Urology. 2017 Mar 30. pii: S0090-4295(17)30297.
    Abstract    



  159. LAVERY HJ, Zaharieva B, McFaddin A, Heerema N, et al
    A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.
    BMC Cancer. 2017;17:247.
    Abstract    

    Abstract available

  160. IDE H, Inoue S, Miyamoto H
    Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
    PLoS One. 2017;12:e0174746.
    Abstract    

    Abstract available

  161. XIE JY, Chen PC, Zhang JL, Gao ZS, et al
    The prognostic significance of DAPK1 in bladder cancer.
    PLoS One. 2017;12:e0175290.
    Abstract    

    Abstract available

  162. ORRE M, Latorzeff I, Flechon A, Roubaud G, et al
    Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
    PLoS One. 2017;12:e0174978.
    Abstract    

    Abstract available

  163. HORI S, Miyake M, Tatsumi Y, Onishi S, et al
    Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
    PLoS One. 2017;12:e0175494.
    Abstract    

    Abstract available

  164. LI M, Wang L
    The Associations of Psychological Stress with Depressive and Anxiety Symptoms among Chinese Bladder and Renal Cancer Patients: The Mediating Role of Resilience.
    PLoS One. 2016;11:e0154729.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;